Suven Life gets four patent approvals for CNS molecules

NEW DELHI: Drug firm Suven Life Sciences today said it has received four product patents for CNS molecules, two from China, one from Mexico and one from New Zealand which could be used for treating various central nervous system disorders.

The product patents are valid through 2028, Suven Life Sciences said in a BSE filing.

The company has received approval for molecules that could be used in the treatment of neuro-degenerative disorders like Parkinson, Alzheimer's disease and Schizophrenia, it added.

Products developed out of these molecules may be out- licensed at various phases of clinical development like Phase I or Phase II, the company said.

Commenting on the development, Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

With these new patents, the company now has a total of 10 patents from China, 14 patents from Mexico and 14 patents from New Zealand, the company said.

Shares of Suven Life Sciences were trading at Rs 28.20 in the after noon trade on BSE, up 1.81 per cent from their previous close.